Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of non-myeloid malignancy and receiving chemotherapy~* Baseline Hb of \<= 11 g/dL~* Planned chemotherapy for a minimum of 15 weeks to be administered every 3 weeks~* Female patients with reproductive potential must have a negative serum pregnancy test at screening.~Exclusion Criteria:~* No uncontrolled hypertension or recent history (within 6 months) of uncontrolled cardiac arrhythmias~* No pulmonary embolism~* or thrombosis~* No transfusion of white blood cells or packed red blood cells within 28 days of Epoetin alfa treatment~* No prior treatment with Epoetin alfa or any other erythropoetic agent within the previous three months

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).